NeuroOne Medical Technologies Corporation NMTC

Agreement Covers Key Southern California Counties Including Los Angeles Metro as NeuroOne Broadens Commercial Access in Key U.S. MarketsEDEN PRAIRIE, Minn., Sept. 17, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on transforming the surgical diagnosis and treatment of neurological disorders, today announced a new Southern California distribution agreement for its FDA-cleared OneRF® Trigeminal

Successful Large-Animal Procedures Build Momentum Toward Planned Launch of the StereoCED(TM) Platform for Human Investigational Clinical Studies Later This Quarter Related StereoCED(TM) Revenue Expected to be Recognized in the Current Fiscal Quarter ...

NeuroOne Medical Technologies Corp (NMTC) reports strong order growth and margin expansion, yet manufacturing bottlenecks and rising costs widen net losses in Q3 fiscal 2026.

Moby summary of NeuroOne Medical Technologies Corporation's Q3 2026 earnings call

$2.7 Million in Product Orders Outpace Shipments of $2.0 Million Company Has Received Product Orders for Fiscal Year 2026 of $11.2 Million; Working with Suppliers to Maximize Product Shipments Through End of Fiscal Year Received ISO 13485 Certifica...

Certification Provides Key Step for the Company Towards Commercializing Internationally and Offering a New Opportunity for Revenue Growth Achievement Highlights the Company's Robust Quality System and Strong Compliance Capabilities EDEN PRAIRIE, MIN...

EDEN PRAIRIE, MINN. - August 3, 2026 (NEWMEDIAWIRE) - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological ...

White Paper Highlights How StereoCED(TM) is Designed to Address Key Barriers to the Scalable Commercial Delivery of Brain Therapeutics Through a Streamlined Robotic-Assisted Workflow Device Availability for Research and Investigational Clinical Studi...

Large, Single-Center Patient Cohort Demonstrates Meaningful Reductions in Seizure Frequency and Severity, While Improving Patient Quality of Life* Growing Real-World Evidence Demonstrates an Emerging Diagnosis-to-Therapy Paradigm through the OneRF(R)...

Growing Interest From Leading Academic Investigators and Biopharmaceutical Companies in NeuroOne's Drug Delivery Platform EDEN PRAIRIE, MINN. - July 16, 2026 (NEWMEDIAWIRE) - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the...

EDEN PRAIRIE, MINN. - June 29, 2026 (NEWMEDIAWIRE) - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological d...

EDEN PRAIRIE, MINN. - June 25, 2026 (NEWMEDIAWIRE) - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological d...

EDEN PRAIRIE, MINN. - June 16, 2026 (NEWMEDIAWIRE) - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological d...

EDEN PRAIRIE, MINN., - June 8, 2026 (NEWMEDIAWIRE) - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological d...

EDEN PRAIRIE, MINN. - May 28, 2026 (NEWMEDIAWIRE) - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological di...

Ongoing Business Not Affected, Company Reaffirms Product Revenue Guidance of at Least $10.5 Million for Fiscal Year 2026 Customer Order Modification at Quarter-End Resulted in Revenue Overstatement of Approximately $0.5 Million and Net Loss Understat...

Moby summary of NeuroOne Medical Technologies Corporation's Q2 2026 earnings call